TGFB1 and breast carcinoma: Although SL4 treatment activated the TGF-β signaling pathway in MDA-MB-231 cells, inhibition of TGF-β signaling by a specific inhibitor did not affect the SL4-induced G2/M phase arrest in breast cancer cells.